AMGN · NMS · Healthcare
Amgen Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 325.38
Market price
USD 385.65
Implied upside
-15.6%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 41.1bn | USD 45.9bn | USD 51.3bn | USD 57.3bn | USD 64.1bn | +11.8% |
| EBIT | USD 11.4bn | USD 12.7bn | USD 14.2bn | USD 15.9bn | USD 17.8bn | +11.8% |
| NOPAT | USD 9.9bn | USD 11.1bn | USD 12.4bn | USD 13.9bn | USD 15.5bn | +11.8% |
| Add depreciation & amortisation | USD 6.0bn | USD 6.7bn | USD 7.5bn | USD 8.3bn | USD 9.3bn | +11.8% |
| Less capital expenditure | USD -6.0bn | USD -6.7bn | USD -7.5bn | USD -8.3bn | USD -9.3bn | +11.8% |
| Less increase in working capital | USD -1.1bn | USD -1.3bn | USD -1.4bn | USD -1.6bn | USD -1.7bn | +11.8% |
| Free cashflow to firm | USD 8.8bn | USD 9.8bn | USD 11.0bn | USD 12.3bn | USD 13.8bn | +11.8% |
| Discount factor | 0.9643 | 0.8966 | 0.8337 | 0.7751 | 0.7207 | - |
| Present value | USD 8.5bn | USD 8.8bn | USD 9.2bn | USD 9.5bn | USD 9.9bn | +3.9% |
| Present Value Of The Forecast | USD 46.0bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.615 | Reported 0.426, pulled toward 1.0 (Blume) |
| Cost of equity | 8.38% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 208.5bn | 79.2% of capital |
| Total debt | USD 54.6bn | 20.8% of capital, book value as a proxy |
| Tax rate | 12.7% | Effective, capped at statutory |
| WACC | 7.55% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
79% of EV
- Forecast FCFF, final year
- USD 13.8bn
- Capex at depreciation, working capital in reinvestment
- USD 15.5bn
- Less reinvestment at g/ROIC (22.5% of NOPAT)
- USD -3.5bn
- Capitalised
- USD 12.0bn
- ROIC (reported)
- 11.1%
- Terminal value, undiscounted
- USD 244.0bn
- Terminal value, discounted
- USD 175.9bn
- Enterprise value
- USD 221.8bn
- Less net debt
- USD 45.5bn
- Equity value
- USD 176.4bn
Exit at 17.8x EBITDA
88% of EV
- Terminal value, undiscounted
- USD 482.7bn
- Terminal value, discounted
- USD 347.9bn
- Enterprise value
- USD 393.9bn
- Less net debt
- USD 45.5bn
- Equity value
- USD 348.4bn
Spread between methods: 66%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 5.55% | 491.63 | 533.96 | 589.84 | 667.26 | 781.96 |
| 6.55% | 376.90 | 398.40 | 424.97 | 458.76 | 503.31 |
| 7.55% | 300.15 | 311.71 | 325.38 | 341.84 | 362.15 |
| 8.55% | 245.23 | 251.51 | 258.69 | 267.00 | 276.78 |
| 9.55% | 203.99 | 207.28 | 210.91 | 214.96 | 219.55 |
Outlined: this model. Green text: above today's price of 385.65. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 11.8% | 15.3% | +3.5pp |
| EBIT margin | 27.7% | 31.7% | +4.0pp |
| Discount rate | 7.5% | 6.9% | -0.7pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.